Silibinin as a major component of milk thistle seed provides promising influences against diabetes and its complications: a systematic review
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-10 · 397 (10) · 7531-7549
DOI: 10.1007/s00210-024-03172-x ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 27.05.2024. Verfasst von Parisa Zare Mehrjerdi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Antioxidants, Hypoglycemic Agents, Silybin, Silybum marianum. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Silibinin, or silybin, is a polyphenolic flavonoid and the main active component of silymarin, isolated from the seeds of the milk thistle plant (Silybum marianum). It has been shown to have antioxidant, antineoplastic, hepatoprotective, neuroprotective, anti-inflammatory, antimicrobial, and antidiabetic effects. In this systematic review, a literature search was conducted from inception until January 2024 on major electronic databases (PubMed, Scopus, Web of Science, and Google Scholar) to identify studies assessing the effects of silibinin on diabetes and its associated complications in different molecular, cellular, animal, and clinical studies. Silibinin has been shown to improve diabetic conditions through a variety of mechanisms, including reducing insulin resistance (IR), lowering reactive oxygen species (ROS) levels, and affecting glycolysis, gluconeogenesis, and glycogenolysis. Silibinin treatment reduced blood glucose (BG) levels, oxidative stress markers, and inflammatory cytokines while increasing glycosylated hemoglobin (HbA1C) and antioxidative marker levels in various cellular and animal models of diabetes. It also ameliorated levels of triglyceride (TG), cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Furthermore, silibinin has been identified as an effective treatment for diabetic complications, including hepatic damage, endothelial dysfunction, neuropathy, nephropathy, retinopathy, and osteoporosis. The promising anti-inflammatory, antioxidant, antidiabetic, and insulin-sensitizing activities of silibinin were also supported in clinical studies. The administration of silibinin could possess multiple protective impacts in improving DM and its complications. Nevertheless, further well-designed investigations are necessary to better understand its mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
- Student Research Committee, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
- Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. baradaranrv@mums.ac.ir.
Zitieren
APA
Zare Mehrjerdi, P., Asadi, S., Ehsani, E., Askari, V. R., & Baradaran Rahimi, V. (2024). Silibinin as a major component of milk thistle seed provides promising influences against diabetes and its complications: a systematic review. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(10), 7531-7549. https://doi.org/10.1007/s00210-024-03172-x
Vancouver
Zare Mehrjerdi P, Asadi S, Ehsani E, Askari VR, Baradaran Rahimi V. Silibinin as a major component of milk thistle seed provides promising influences against diabetes and its complications: a systematic review. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(10):7531-7549. doi:10.1007/s00210-024-03172-x
BibTeX
@article{ZareMehrjerdi2024,
author = {Zare Mehrjerdi, Parisa and Asadi, Sara and Ehsani, Elham and Askari, Vahid Reza and Baradaran Rahimi, Vafa},
title = {Silibinin as a major component of milk thistle seed provides promising influences against diabetes and its complications: a systematic review},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
volume = {397},
number = {10},
pages = {7531--7549},
doi = {10.1007/s00210-024-03172-x}
}
EUVIMED